Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.96 |
| ▸ | LTA4H | P09960 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | GLA | P06280 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CASP1 | P29466 | 2/20 | 0.47 |
| ▸ | CASP7 | P55210 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31680393 | 0.98 | DPP4 (0.93) | DPP4LTA4HALDH1A1GLAMAPT | |
| SCHEMBL498783 | 0.98 | DPP4 (1.00) | DPP4LTA4HALDH1A1GLAMAPT | |
| SCHEMBL21823759 | 0.83 | LTA4H (0.71) | DPP4LTA4HALDH1A1GLAMAPT | |
| SCHEMBL499162 | 0.83 | DPP4 (0.74) | DPP4LTA4HALDH1A1GLAMAPT | |
| SCHEMBL8572801 | 0.82 | MEN1 (0.70) | DPP4LTA4HALDH1A1GLAMAPT | |
| SCHEMBL8575618 | 0.82 | DPP4 (0.67) | DPP4LTA4HALDH1A1GLAMAPT | |
| SCHEMBL8827220 | 0.81 | DPP4 (0.66) | DPP4LTA4HALDH1A1GLAMAPT | |
| SCHEMBL8576605 | 0.80 | DPP4 (0.69) | DPP4LTA4HALDH1A1GLAMAPT | |
| SCHEMBL8827063 | 0.80 | DPP4 (0.64) | DPP4LTA4HALDH1A1GLAMAPT | |
| SCHEMBL8575790 | 0.80 | LTA4H (0.67) | DPP4LTA4HALDH1A1GLAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7196646-A | — | — | None | — | — | JP | disclosed |
| EP-2595975-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | Corning Incorporated (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| WO-2012012278-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012278-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED (US) | 2012-01-26 | — | — | WO | disclosed |
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-09 | — | — | US | disclosed |
| EP-2194045-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2010-06-09 | — | — | EP | disclosed |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-0904076-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-03-31 | — | — | EP | disclosed |
| US-5874452-A | Biheteroaryl inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-02-23 | — | — | US | disclosed |
| WO-1998023269-A1 | POLYTHIOPHENE ANTI-TUMOR AGENTS | PURDUE RESEARCH FOUNDATION (US) | 1998-06-04 | — | — | WO | disclosed |
| US-5753692-A | PLANT EXTRACTS, IMMUNOSTIMULANTS TREATING IMMUNODEFICIENCY DISEASES | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1998-05-19 | — | — | US | disclosed |
| US-5747525-A | ANTITUMOR AGENTS OF OLIGOMERS OF THIOPHENE | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1998-05-05 | — | — | US | disclosed |
| US-5741811-A | ADMINISTERING TO CANCER PATIENTS | PURDUE RESEARCH FOUNDATION (US) | 1998-04-21 | — | — | US | disclosed |
| WO-1997036585-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-09 | — | — | WO | disclosed |
| US-5602170-A | ADMINISTERING ANTIIFLAMMATORY AGENT | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 1997-02-11 | — | — | US | disclosed |
| US-5578636-A | Polythiophene anti-tumor agents | PURDUE RESEARCH FOUNDATION (US) | 1996-11-26 | — | — | US | disclosed |
| JP-H07196646-A | HYDROXYMETHYLOPOLYTHIOPHENE DERIVATIVE | IND TECHNOL RES INST | 1995-08-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227846-A1 | SUBSTITUTED PYRAZOLE DERIVATIVE | AR, NR5A1, NR3C2 | DPP4 4209/4885LTA4H 4192/4885ALDH1A1 809/4885 |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | GPR35, GPR65, GPR68 | DPP4 3281/4885LTA4H 1196/4885ALDH1A1 1572/4885 |
| US-20090270359-A1 | SUBSTITUTED PYRAZOLE DERIVATIVES | AR, NR5A1, NR3C2 | DPP4 4260/4885LTA4H 4191/4885ALDH1A1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.